Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Trial Profile

Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Astrocytoma; Glioma; Neurofibromatosis 1
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2021 protocol was amended and approved by all regulatory groups (PBTC Scientific Committee,the PBTC DSMB and CTEP) to expand accrual to 25 patients in an effort to provide patients with a potentially beneficial treatment and evaluate further responses, toxicities, and survival in a descriptive fashion
    • 01 Oct 2021 Results (n=25) of stratum 4 ,patients with sporadic (not associated with NF1) recurrent and progressive OPHGs published in the Neuro-Oncology
    • 02 Apr 2021 Planned primary completion date changed from 31 Dec 2022 to 1 Dec 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top